Literature DB >> 21228268

Dietary zinc and prostate cancer survival in a Swedish cohort.

Mara M Epstein1, Julie L Kasperzyk, Ove Andrén, Edward L Giovannucci, Alicja Wolk, Niclas Håkansson, Swen-Olof Andersson, Jan-Erik Johansson, Katja Fall, Lorelei A Mucci.   

Abstract

BACKGROUND: Zinc is involved in many essential cellular functions, including DNA repair and immune system maintenance. Although experimental evidence supports a role for zinc in prostate carcinogenesis, epidemiologic data are inconsistent; no data on cancer-specific survival have been reported.
OBJECTIVE: Our objective was to determine whether dietary zinc assessed near the time of prostate cancer diagnosis is associated with improved disease-specific survival.
DESIGN: This population-based cohort consists of 525 men aged <80 y from Örebro County, Sweden, with a diagnosis of prostate cancer made between 1989 and 1994. Study participants completed self-administered food-frequency questionnaires, and zinc intake was derived from nutrient databases. Cox proportional hazards regression was used to estimate multivariate hazard ratios (HRs) and 95% CIs for time to death from prostate cancer as well as death from all causes through February 2009 by quartile (Q) of dietary zinc intake. Models were also stratified by disease stage at diagnosis (localized or advanced).
RESULTS: With a median follow-up of 6.4 y, 218 (42%) men died of prostate cancer and 257 (49%) died of other causes. High dietary zinc intake was associated with a reduced risk of prostate cancer-specific mortality (HR(Q4 vs Q1): 0.64; 95% CI: 0.44, 0.94; P for trend = 0.05) in the study population. The association was stronger in men with localized tumors (HR: 0.24; 95% CI: 0.09, 0.66; P for trend = 0.005). Zinc intake was not associated with mortality from other causes.
CONCLUSION: These results suggest that high dietary intake of zinc is associated with lower prostate cancer-specific mortality after diagnosis, particularly in men with localized disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21228268      PMCID: PMC3041600          DOI: 10.3945/ajcn.110.004804

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  40 in total

1.  Dietary reference intakes: vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc.

Authors:  P Trumbo; A A Yates; S Schlicker; M Poos
Journal:  J Am Diet Assoc       Date:  2001-03

2.  Vitamin and mineral supplement use is associated with reduced risk of prostate cancer.

Authors:  A R Kristal; J L Stanford; J H Cohen; K Wicklund; R E Patterson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1999-10       Impact factor: 4.254

Review 3.  Zinc and the immune system.

Authors:  L Rink; P Gabriel
Journal:  Proc Nutr Soc       Date:  2000-11       Impact factor: 6.297

Review 4.  Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolve.

Authors:  L C Costello; P Feng; B Milon; M Tan; R B Franklin
Journal:  Prostate Cancer Prostatic Dis       Date:  2004       Impact factor: 5.554

5.  Diet and prostatic cancer: a case-control study in Hawaii.

Authors:  L N Kolonel; C N Yoshizawa; J H Hankin
Journal:  Am J Epidemiol       Date:  1988-05       Impact factor: 4.897

6.  Zinc in the human prostate gland: normal, hyperplastic and cancerous.

Authors:  T V Sviridova; S V Zaichick
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

7.  Zinc supplement use and risk of prostate cancer.

Authors:  Michael F Leitzmann; Meir J Stampfer; Kana Wu; Graham A Colditz; Walter C Willett; Edward L Giovannucci
Journal:  J Natl Cancer Inst       Date:  2003-07-02       Impact factor: 13.506

Review 8.  Bioavailability of iron, zinc, and other trace minerals from vegetarian diets.

Authors:  Janet R Hunt
Journal:  Am J Clin Nutr       Date:  2003-09       Impact factor: 7.045

9.  Adult dietary intake and prostate cancer risk in Utah: a case-control study with special emphasis on aggressive tumors.

Authors:  D W West; M L Slattery; L M Robison; T K French; A W Mahoney
Journal:  Cancer Causes Control       Date:  1991-03       Impact factor: 2.506

10.  Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County.

Authors:  H Shimizu; R K Ross; L Bernstein; R Yatani; B E Henderson; T M Mack
Journal:  Br J Cancer       Date:  1991-06       Impact factor: 7.640

View more
  23 in total

1.  Evidence that Human Prostate Cancer is a ZIP1-Deficient Malignancy that could be Effectively Treated with a Zinc Ionophore (Clioquinol) Approach.

Authors:  Leslie C Costello; Renty B Franklin; Jing Zou; Michael J Naslund
Journal:  Chemotherapy (Los Angel)       Date:  2015-06

Review 2.  The strategies to control prostate cancer by chemoprevention approaches.

Authors:  Harold Ting; Gagan Deep; Chapla Agarwal; Rajesh Agarwal
Journal:  Mutat Res       Date:  2014-01-02       Impact factor: 2.433

Review 3.  Metabolic targets for potential prostate cancer therapeutics.

Authors:  Jeffrey Twum-Ampofo; De-Xue Fu; Antonino Passaniti; Arif Hussain; M Minhaj Siddiqui
Journal:  Curr Opin Oncol       Date:  2016-05       Impact factor: 3.645

4.  Resveratrol-zinc combination for prostate cancer management.

Authors:  Chandra K Singh; Anna Pitschmann; Nihal Ahmad
Journal:  Cell Cycle       Date:  2014-05-27       Impact factor: 4.534

5.  The cytotoxic and pro-apoptotic activities of the novel fluoropyrimidine F10 towards prostate cancer cells are enhanced by Zn(2+) -chelation and inhibiting the serine protease Omi/HtrA2.

Authors:  William H Gmeiner; Olcay Boyacioglu; Christopher H Stuart; Jamie Jennings-Gee; K C Balaji
Journal:  Prostate       Date:  2014-11-18       Impact factor: 4.104

Review 6.  Decreased zinc in the development and progression of malignancy: an important common relationship and potential for prevention and treatment of carcinomas.

Authors:  Leslie C Costello; Renty B Franklin
Journal:  Expert Opin Ther Targets       Date:  2016-12-05       Impact factor: 6.902

7.  miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells.

Authors:  Brittany L Mihelich; Ekaterina A Khramtsova; Nicole Arva; Avani Vaishnav; Daniel N Johnson; Angeline A Giangreco; Elena Martens-Uzunova; Omar Bagasra; André Kajdacsy-Balla; Larisa Nonn
Journal:  J Biol Chem       Date:  2011-11-01       Impact factor: 5.157

8.  A prospective study of intakes of zinc and heme iron and colorectal cancer risk in men and women.

Authors:  Xuehong Zhang; Edward L Giovannucci; Stephanie A Smith-Warner; Kana Wu; Charles S Fuchs; Michael Pollak; Walter C Willett; Jing Ma
Journal:  Cancer Causes Control       Date:  2011-09-11       Impact factor: 2.506

Review 9.  Zinc and zinc transporters in prostate carcinogenesis.

Authors:  Vladimir Kolenko; Ervin Teper; Alexander Kutikov; Robert Uzzo
Journal:  Nat Rev Urol       Date:  2013-03-12       Impact factor: 14.432

Review 10.  Dietary factors and risk for advanced prostate cancer.

Authors:  Wambui G Gathirua-Mwangi; Jianjun Zhang
Journal:  Eur J Cancer Prev       Date:  2014-03       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.